Asia Pacific Radiopharmaceuticals Market Growth, Size, Trends Analysis - By Product, By Application, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Description

Asia Pacific Radiopharmaceuticals Market Introduction and Overview

According to SPER market research, 'Asia Pacific Radiopharmaceuticals Market Size- By Product, By Application, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Asia Pacific Radiopharmaceuticals Market is predicted to reach 5.89 billion by 2034 with a CAGR of 10.76%.

The radiopharmaceuticals market is the industry that creates, produces, and distributes radioactive compounds, which are primarily used to diagnose and cure diseases. These chemicals, known as radiopharmaceuticals, combine a radioactive isotope and a physiologically active molecule to target specific organs, tissues, or cells in the body. They are widely employed in nuclear medicine and play an important part in imaging techniques such as PET and SPECT scans, as well as targeted cancer treatments.

Restraints: Several constraints limit the growth of the Asia-Pacific radiopharmaceuticals market. Radiopharmaceuticals are expensive due to the high manufacturing costs associated with cyclotrons, reactors, and stringent quality controls. Regulatory complexity and stringent safety standards cause product approvals to be delayed and operational burdens to rise.

Scope of the report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered Product, By Application, By End User

Regions covered

Japan, China, India, Singapore, Australia, South Korea, New Zealand, Thailand, Philippines

Companies Covered

Nordion Inc, Bracco, IRE - IRE ELiT - BE, NTP, ANSTO, ECZACIBAAzI-MONROL, Lantheus, Eckert & Ziegler, Mallinckrodt company, Cardinal Health.

Asia Pacific Radiopharmaceuticals Market Segmentation:

By Product: Based on the Product, Asia Pacific Radiopharmaceuticals Market is segmented as; Diagnostics, Therapeutics.

By Application: Based on the Application, Asia Pacific Radiopharmaceuticals Market is segmented as; Cardiology, Neurology, Oncology, Thyroid, Lymphoma, Endocrine Tumor, Pulmonary Scans, Urology, Others.

By End User: Based on the End User, Asia Pacific Radiopharmaceuticals Market is segmented as; Hospitals, Diagnostic Centres, Others.

By Region: This research also includes data for Japan, China, India, Singapore, Australia, South Korea, New Zealand, Thailand, Philippines.

Product Code: HLCA25208

1.Introduction

1.1.Scope of the report
1.2.Market segment analysis

2.Research Methodology

2.1.Research data source
- 2.1.1.Secondary Data
- 2.1.2.Primary Data
- 2.1.3.SPERs internal database
- 2.1.4.Premium insight from KOLs
2.2.Market size estimation
- 2.2.1.Top-down and Bottom-up approach
2.3.Data triangulation

3.Executive Summary

4.Market Dynamics

4.1.Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1.Drivers
- 4.1.2.Restraints
- 4.1.3.Opportunities
- 4.1.4.Challenges

5.Market variable and outlook

5.1.SWOT Analysis
- 5.1.1.Strengths
- 5.1.2.Weaknesses
- 5.1.3.Opportunities
- 5.1.4.Threats
5.2.PESTEL Analysis
- 5.2.1.Political Landscape
- 5.2.2.Economic Landscape
- 5.2.3.Social Landscape
- 5.2.4.Technological Landscape
- 5.2.5.Environmental Landscape
- 5.2.6.Legal Landscape
5.3.PORTERs Five Forces
- 5.3.1.Bargaining power of suppliers
- 5.3.2.Bargaining power of buyers
- 5.3.3.Threat of Substitute
- 5.3.4.Threat of new entrant
- 5.3.5.Competitive rivalry
5.4.Heat Map Analysis

6.Competitive Landscape

6.1.Asia Pacific Radiopharmaceuticals Market Manufacturing Base Distribution, Sales Area, Product Type
6.2.Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Asia Pacific Radiopharmaceuticals Market

7.Asia Pacific Radiopharmaceuticals Market, By Product (USD Million) 2021-2034

7.1.Diagnostics
7.2.Therapeutics

8.Asia Pacific Radiopharmaceuticals Market, By Application (USD Million) 2021-2034

8.1.Cardiology
8.2.Neurology
8.3.Oncology
8.4.Thyroid
8.5.Lymphoma
8.6.Endocrine Tumor
8.7.Pulmonary Scans
8.8.Urology
8.9.Others

9.Asia Pacific Radiopharmaceuticals Market, By End User (USD Million) 2021-2034

9.1.Hospitals
9.2.Diagnostic Centres
9.3.Others

10.Asia Pacific Radiopharmaceuticals Market, (USD Million) 2021-2034

10.1.Asia Pacific Radiopharmaceuticals Market Size and Market Share

11.Asia Pacific Radiopharmaceuticals Market, By Region, (USD Million) 2021-2034

11.1.Japan
11.2.China
11.3.India
11.4.Singapore
11.5.Australia
11.6.South Korea
11.7.New Zealand
11.8.Thailand
11.9.Philippines

12.Company Profile

12.1.ANSTO
- 12.1.1.Company details
- 12.1.2.Financial outlook
- 12.1.3.Product summary
- 12.1.4.Recent developments
12.2.Bracco
- 12.2.1.Company details
- 12.2.2.Financial outlook
- 12.2.3.Product summary
- 12.2.4.Recent developments
12.3.Cardinal Health
- 12.3.1.Company details
- 12.3.2.Financial outlook
- 12.3.3.Product summary
- 12.3.4.Recent developments
12.4.Eckert & Ziegler
- 12.4.1.Company details
- 12.4.2.Financial outlook
- 12.4.3.Product summary
- 12.4.4.Recent developments
12.5.ECZACIBAAzI-MONROL
- 12.5.1.Company details
- 12.5.2.Financial outlook
- 12.5.3.Product summary
- 12.5.4.Recent developments
12.6.IRE - IRE ELiT - BE
- 12.6.1.Company details
- 12.6.2.Financial outlook
- 12.6.3.Product summary
- 12.6.4.Recent developments
12.7.Lantheus
- 12.7.1.Company details
- 12.7.2.Financial outlook
- 12.7.3.Product summary
- 12.7.4.Recent developments
12.8.Mallinckrodt Company
- 12.8.1.Company details
- 12.8.2.Financial outlook
- 12.8.3.Product summary
- 12.8.4.Recent developments
12.9.Nordion Inc
- 12.9.1.Company details
- 12.9.2.Financial outlook
- 12.9.3.Product summary
- 12.9.4.Recent developments
12.10.NTP
- 12.10.1.Company details
- 12.10.2.Financial outlook
- 12.10.3.Product summary
- 12.10.4.Recent developments
12.11.Others